Circadian Patterns in Postvoid Residual and Voided Percentage among Older Women with Urinary Incontinence
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Study Protocol
2.3. Materials
2.4. Statistical Analysis
3. Results
3.1. Study Population
3.2. FVCPVR Characteristics
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; Van Kerrebroeck, P.; Victor, A.; Wein, A. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003, 61, 37–49. [Google Scholar] [CrossRef]
- Diaz, D.C.; Robinson, D.; Bosch, R.; Costantini, E.; Cotterill, N.; Espuna-Pons, M.; Kocjancic, E.; Lemos, N.; Tarcan, T.; Yoshida, M. Initial assessment of urinary incontinence in adult male and female patients. In Incontinence 6th Edition ICI-ICS; Abrams, P., Cardozo, L., Wagg, A., Wein, A., Eds.; International Continence Society: Bristol, UK, 2017; pp. 495–540. [Google Scholar]
- Rosier, P.; Schaefer, W.; Lose, G.; Goldman, H.; Guralnick, M.; Eustice, S.; Dickinson, T.; Hashim, H. International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol. Urodyn. 2017, 36, 1243–1260. [Google Scholar] [CrossRef]
- Memon, A.; Ather, M.H. Use of residual fraction instead of residual volume in the evaluation of lower urinary tract symptoms. Tech. Urol. 2000, 6, 26–28. [Google Scholar]
- Asimakopoulos, A.; De Nunzio, C.; Kocjancic, E.; Tubaro, A.; Rosier, P.; Finazzi-Agrò, E. Measurement of post-void residual urine. Neurourol. Urodyn. 2016, 35, 55–57. [Google Scholar] [CrossRef]
- Wein, A.; Lee, D. Benign prostatic hyperplasia and related entities. In Penn Clinical Manual of Urology; Hanno, P., Wein, A., Malkowicz, B., Eds.; Saunders: Philadelphia, Pennsylvania, 2007; pp. 479–521. [Google Scholar]
- Gehrich, A.; Stany, M.; Fischer, J.; Buller, J.; Zahn, C. Establishing a mean postvoid residual volume in asymptomatic perimenopausal and postmenopausal women. Obstet. Gynecol. 2007, 110, 827–832. [Google Scholar] [CrossRef]
- Tseng, L.-H.; Liang, C.-C.; Chang, Y.-L.; Lee, S.-J.; Lloyd, L.K.; Chen, C.-K. Postvoid residual urine in women with stress incontinence. Neurourol. Urodyn. 2008, 27, 48–51. [Google Scholar] [CrossRef]
- Fitzgerald, M.; Jaffar, J.; Brubaker, L. Risk factors for elevated postvoid residual in women with symptoms of urinary urgency, frequency and urge incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2001, 12, 237–239. [Google Scholar] [CrossRef]
- Lunacek, L.; Gärtner, M.; Krhut, J.; Mika, D.; Sykora, R.; Zvara, P. Evaluation of intra-individual test-re-test variability of uroflowmetry in healthy women and women suffering from stress, urge, and mixed urinary incontinence. Int. Urogynecol. J. 2018, 29, 1523–1527. [Google Scholar] [CrossRef]
- Griffiths, D.J.; Harrison, G.; Moore, K.; McCracken, P. Variability of post-void residual urine volume in the elderly. Urol. Res. 1996, 24, 23–26. [Google Scholar] [CrossRef]
- Tsoi, K.; Chan, J.; Hirai, H.; Wong, S.; Kwok, T. Cognitive tests to detect dementia: A systematic review and meta-analysis. JAMA Intern. Med. 2015, 175, 1450–1458. [Google Scholar] [CrossRef] [Green Version]
- Goessaert, A.S.; Krott, L.; Hoebeke, P.; Vande Walle, J.; Everaert, K. Diagnosing the pathophysiologic mechanisms of nocturnal polyuria. Eur. Urol. 2015, 67, 283–288. [Google Scholar] [CrossRef]
- Rijksinstituut voor Ziekte- en Invaliditeitsverzekering. (sd). Belgian Modified Katz Scale. Available online: https://www.riziv.fgov.be/SiteCollectionDocuments/formulier_verpleegkundige_evaluatieschaal.pdf (accessed on 8 March 2019).
- Gobbens, R.; van Assen, M.; Luijkx, K.; Wijnen-Sponselee, M.; Schols, J. The Tilburg Frailty Indicator: Psychometric properties. J. Am. Med. Dir. Assoc. 2010, 11, 344–355. [Google Scholar] [CrossRef]
- Oliver, D.; Britton, M.; Seed, P.; Martin, F.; Hopper, A. Development and evaluation of evidence based risk assessment tool (STRATIFY) to predict which elderly inpatients will fall: Case-control and cohort studies. BMJ 1997, 315, 1049–1053. [Google Scholar] [CrossRef] [Green Version]
- Brookes, S.; Donovan, J.; Wright, M.; Jackson, S.; Abrams, P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: Data from a randomized controlled trial of surgery for women with stress incontinence. Am. J. Obstet. Gynecol. 2004, 191, 73–82. [Google Scholar] [CrossRef]
- Wallace, M.; Shelkey, M. Harford Institute for Geriatric Nursing. Katz Index of Independence in Activities of Daily Living (ADL). Urol. Nurs. 2007, 27, 93–94. [Google Scholar]
- Al-Shaikh, G.; Larochelle, A.; Campbell, C.; Schachter, J.; Baker, K.; Pascali, D. Accuracy of bladder scanning in the assessment of postvoid residual volume. J. Obstet. Gynaecol. Can. 2009, 31, 526–532. [Google Scholar] [CrossRef]
- D’Ancona, C.; Haylen, B.; Oelke, M.; Abranches-Monteiro, L.; Arnold, E.; Goldman, H.; Hamid, R.; Homma, Y.; Marcelissen, T.; Rademakers, K.; et al. Standardisation Steering Committee ICS and the ICS Working Group on Terminology for Male Lower Urinary Tract & Pelvic Floor Symptoms and Dysfunction. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol. Urodyn. 2019, 38, 433–477. [Google Scholar] [CrossRef]
- Tikkinen, K.; Johnson, T.M., 2nd; Tammela, T.; Sintonen, H.; Haukka, J.; Huhtala, H.; Auvinen, A. Nocturia frequency, bother, and quality of life: How often is too often? A population-based study in Finland. Eur. Urol. 2010, 57, 488–496. [Google Scholar] [CrossRef]
- Schäfer, W.; Abrams, P.; Liao, L.; Mattiasson, A.; Pesce, F.; Spangberg, A.; Sterling, A.; Zinner, N.; van Kerrebroeck, P. International Continence Society. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol. Urodyn. 2002, 21, 261–274. [Google Scholar] [CrossRef]
- Stevens, P.; Levin, A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 2013, 158, 825–830. [Google Scholar] [CrossRef] [Green Version]
- Kelly, C. Evaluation of voiding dysfunction and measurement of bladder volume. Rev. Urol. 2004, 6, S32–S37. [Google Scholar]
- Saaby, M.L.; Lose, G. Repeatability of post-void residual urine > 100 mL in urogynaecologic patients. Int. Urogynecol. J. 2012, 23, 207–209. [Google Scholar] [CrossRef]
- Van Haarst, E.; Bosch, J. The optimal duration of frequency-volume charts related to compliance and reliability. Neurourol. Urodyn. 2014, 33, 296–301. [Google Scholar] [CrossRef]
Variable | All Patients (n = 90) | SUI (n = 28) | UUI (n = 36) | MUI (n = 26) | p-Value |
---|---|---|---|---|---|
Age (years) | 76 (74–78) | 74 (71–78) | 77 (73–79) | 78 (74–80) | 0.345 |
BMI (kg/m2) | 28 (27–29) | 28 (26–32) | 28 (25–31) | 28 (26–29) | 0.872 |
Gynecological history | |||||
Parity | 2 (2–3) | 2 (1–3) | 3 (2–3) | 2 (1–3) | 0.228 |
vaginal deliveries | 2 (2–2) | 2 (1–2) | 2 (2–3) | 1 (1–2) | 0.186 |
cesarean deliveries | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.382 |
Hysterectomy | 33 (37%) | 16 (57%) | 10 (28%) | 7 (27%) | 0.031 * |
Prolapse | 68 (76%) | 22 (79%) | 25 (70%) | 21 (81%) | 0.583 |
Comorbid conditions | |||||
Chronic kidney disease | 14 (15%) | 1 (4%) | 8 (22%) | 5 (19%) | 0.090 |
Stage 3 | 12 (13%) | 1 (4%) | 7 (19%) | 4 (15%) | |
Stage 4 | 1 (1%) | 0 | 1 (3%) | 0 | |
Stage 5 | 1 (1%) | 0 | 0 | 1 (4%) | |
Diabetes mellitus | 18 (20%) | 8 (29%) | 9 (25%) | 1 (4%) | 0.051 |
Chronic obstructive pulmonary disease | 9 (10%) | 4 (14%) | 3 (8%) | 2 (8%) | 0.744 |
Congestive heart failure | 9 (10%) | 3 (11%) | 4 (11%) | 2 (8%) | 0.908 |
Lower extremity venous insufficiency | 40 (44%) | 11 (39%) | 18 (50%) | 11(42%) | 0.687 |
Sleep apnoea | 5 (6%) | 2 (7%) | 3 (8%) | 0 | 0.371 |
Severe constipation | 21 (23%) | 7 (25%) | 9 (25%) | 5 (20%) | 0.859 |
Depression | 15 (17%) | 1 (4%) | 9 (25%) | 5 (20%) | 0.048 * |
Neurological Disorders | 18 (20%) | 1 (4%) | 11 (31%) | 6 (23%) | 0.023 * |
Stroke | 7 (8%) | 0 | 7 (20%) | 0 | |
Parkinson’s disease | 4 (4%) | 0 | 2 (6%) | 2 (8%) | |
Normal pressure hydrocephalus | 1 (1%) | 0 | 0 | 1 (4%) | |
Dementia | 2 (2%) | 0 | 1 (3%) | 1 (4%) | |
Inflammatory disease of CNS | 1 (1%) | 0 | 1 (3%) | 0 | |
Peripheral neuropathy due to iatrogenic lesions | 1 (1%) | 1 (4%) | 0 | 0 | |
Postpolio syndrome | 1 (1%) | 0 | 0 | 1 (4%) | |
Spinal canal stenosis | 3 (3%) | 0 | 2 (6%) | 1 (4%) | |
Medications | |||||
Total medications | 6 (5–7) | 7 (5–8) | 6 (4–7) | 5 (3–7) | 0.460 |
α-adrenergic agonists | 8 (9%) | 4 (14%) | 3 (8%) | 1 (4%) | 0.475 |
α-adrenergic antagonists | 0 | 0 | 0 | 0 | - |
Angiotensin converting enzyme inhibitors | 9 (10%) | 4 (14%) | 2 (6%) | 3 (12%) | 0.553 |
Anticholinergics | 5 (6%) | 1 (4%) | 3 (8%) | 1 (4%) | 0.729 |
Calcium channel blockers | 17 (19%) | 6 (21%) | 4 (11%) | 7 (27%) | 0.268 |
Cholinesterase inhibitors | 3 (3%) | 0 | 3 (8%) | 0 | 0.111 |
Diuretics | 18 (20%) | 4 (14%) | 9 (25%) | 5 (19%) | 0.601 |
Loop diuretics | 7 (8%) | 1 (4%) | 4 (11%) | 2 (8%) | |
Thiazide diuretics | 2 (2%) | 0 | 0 | 2 (8%) | |
Potassium-sparing diuretics | 3 (3%) | 1 (4%) | 1 (3%) | 1 (4%) | |
Carbonic anhydrase inhibitors | 0 | 0 | 0 | 0 | |
Combination: loop and potassium sparing diuretics | 2 (2%) | 1 (4%) | 1 (3%) | 0 | |
Combination: thiazide and potassium sparing diuretics | 4 (4%) | 1 (4%) | 3 (8%) | 0 | |
Opioids | 14 (16%) | 5 (18%) | 6 (17%) | 3 (12%) | 0.817 |
Sedatives/hypnotics | 16 (18%) | 5 (18%) | 7 (19%) | 4 (15%) | 0.941 |
Antipsychotics | 3 (3%) | 1 (4%) | 2 (6%) | 0 | 0.777 |
H1 blockers | 10 (11%) | 5 (18%) | 3 (8%) | 2 (8%) | 0.481 |
Selective serotonin reuptake inhibitors | 16 (18%) | 1 (4%) | 10 (28%) | 5 (20%) | 0.032 * |
Sodium-glucose cotransporter 2 inhibitors | 0 | 0 | 0 | 0 | - |
Variable | All Patients (n = 90) | SUI (n = 28) | UUI (n = 36) | MUI (n = 26) | p-Value |
---|---|---|---|---|---|
Independence in ADLs (Katz Index) Total score (0–6) | <0.001 * | ||||
Severe Impairment (0–2) | 13 (14%) | 0 (0%) | 11 (31%) | 2 (8%) | |
Moderate Impairment (3–4) | 18 (20%) | 2 (7%) | 8 (22%) | 8 (31%) | |
Well-preserved function (5–6) | 59 (66%) | 26 (93%) | 17 (47%) | 16 (62%) | |
Frailty (TFI) Total score (0–15) | 0.017 * | ||||
Nonfrail (0–4) | 26 (30%) | 13 (48%) | 5 (15%) | 8 (32%) | |
Frail (5–15) | 60 (70%) | 14 (52%) | 29 (85%) | 17 (68%) | |
Fall risk factors (STRATIFY) Total score (0–5) | 0.201 | ||||
Low/moderate risk (0–1) | 51 (57%) | 20 (71%) | 18 (50%) | 13 (52%) | |
High risk (2–5) | 38 (43%) | 8 (29%) | 18 (50%) | 12 (48%) | |
Lower urinary tract symptoms (ICIQ-fLUTS) | |||||
Total score—Filling (0–16) | 6 (6–7) | 6 (5–6) | 7 (6–7) | 7 (5–9) | 0.167 |
Total score—Voiding (0–12) | 1 (0–2) | 1 (0–2) | 2 (0–4) | 1 (0–2) | 0.346 |
Total score—Incontinence (0–20) | 11 (10–12) | 11 (10–12) | 11 (8–13) | 11 (9–14) | 0.823 |
All Patients (n = 90) | SUI (n = 28) | UUI (n = 36) | MUI (n = 26) | p-Value | |
---|---|---|---|---|---|
24-h volume (mL) | 2086 (1827–2260) | 2549 (2120–2852) | 1747 (1430–2000) | 2173 (1827–2523) | <0.001 * |
Global polyuria (24-h urine output > 40 mL/kg) | 18 (20%) | 8 (29%) | 2 (6%) | 8 (31%) | 0.013 * |
Nocturia (≥2 voids/night) | 60 (67%) | 19 (68%) | 22 (61%) | 19 (73%) | 0.586 |
Nocturnal polyuria (NPi > 33%) | 63 (70%) | 17 (85%) | 25 (74%) | 12 (67%) | 0.294 |
Number of voids (24 h) | 9 (8–9) | 9 (8–10) | 8 (7–9) | 10 (9–12) | 0.005 * |
Mean VV (mL) | 200 (180–241) | 291 (233–325) | 177 (157–200) | 181 (151–245) | <0.001 * |
Max VV (mL) | 380 (340–400) | 470 (400–500) | 335 (225–400) | 320 (250–400) | <0.001 * |
Total UI weight (g) | 45 (19–90) | 15 (0–46) | 88 (14–265) | 48 (22–236) | 0.040 * |
Mean 24-h PVR (mL) | 26 (20–36) | 28 (16–39) | 27 (10–43) | 24 (11–45) | 0.837 |
Mean daytime PVR (mL) | 20 (11–30) | 22 (10–44) | 17 (7–32) | 22 (4–37) | 0.658 |
Mean nighttime PVR (mL) | 20 (12–42) | 20 (9–68) | 16 (3–44) | 31 (10–55) | 0.511 |
Max 24-h PVR (mL) | 92 (67–135) | 105 53–156) | 77 (40–126) | 115 (63–191) | 0.463 |
Mean 24-h Void% (%) | 90 (87–90) | 91 (87–94) | 89 (80–95) | 91 (85–95) | 0.729 |
Mean daytime Void% (%) | 91 (88–94) | 91 (85–96) | 91 (82–96) | 92 (84–98) | 0.876 |
Mean nighttime Void% (%) | 91 (87–96) | 94 (84–98) | 92 (83–98) | 91 (84–98) | 0.884 |
Min 24-h Void% (%) | 64 (56–72) | 68 (58–75) | 59 (49–81) | 64 (41–83) | 0.555 |
All Patients (n = 90) | SUI (n = 28) | UUI (n = 36) | MUI (n = 26) | p-Value | |
---|---|---|---|---|---|
Mean 24-h PVR | 0.781 | ||||
<50 mL | 66 (73%) | 20 (71%) | 27 (75%) | 19 (73%) | |
50–100 mL | 18 (20%) | 7 (25%) | 7 (19%) | 4 (15%) | |
>100 mL | 6 (7%) | 1 (4%) | 2 (6%) | 3 (12%) | |
Max daytime PVR | 0.499 | ||||
<50 mL | 39 (43%) | 11 (39%) | 16 (44%) | 12 (46%) | |
50–100 mL | 21 (23%) | 8 (29%) | 10 (28%) | 3 (12%) | |
>100 mL | 30 (33%) | 9 (32%) | 10 (28%) | 11 (42%) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Decalf, V.; Monaghan, T.F.; Denys, M.-A.; Petrovic, M.; Pieters, R.; Weiss, J.P.; Everaert, K. Circadian Patterns in Postvoid Residual and Voided Percentage among Older Women with Urinary Incontinence. J. Clin. Med. 2020, 9, 922. https://doi.org/10.3390/jcm9040922
Decalf V, Monaghan TF, Denys M-A, Petrovic M, Pieters R, Weiss JP, Everaert K. Circadian Patterns in Postvoid Residual and Voided Percentage among Older Women with Urinary Incontinence. Journal of Clinical Medicine. 2020; 9(4):922. https://doi.org/10.3390/jcm9040922
Chicago/Turabian StyleDecalf, Veerle, Thomas F. Monaghan, Marie-Astrid Denys, Mirko Petrovic, Ronny Pieters, Jeffrey P. Weiss, and Karel Everaert. 2020. "Circadian Patterns in Postvoid Residual and Voided Percentage among Older Women with Urinary Incontinence" Journal of Clinical Medicine 9, no. 4: 922. https://doi.org/10.3390/jcm9040922